Universe Pharmaceuticals (UPC) Short term Debt (2020 - 2025)

Universe Pharmaceuticals has disclosed Short term Debt across 6 years of filings, most recently posting $2.1 billion for Q3 2025.

• Short term Debt for Q3 2025 came in at $2.1 billion, down 64.02% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.1 billion (down 64.02% YoY), and the FY2025 annual result was $2.1 billion, down 64.02% from the prior year.
• Short term Debt came in at $2.1 billion for Q3 2025 at Universe Pharmaceuticals, down from $5.9 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.9 billion in Q3 2024 to a low of $7293.0 in Q1 2022.
• The 5-year median for Short term Debt is $5.5 million (2023), against an average of $997.9 million.
• Across the five-year window, Short term Debt tumbled 100.0% in 2021 and surged 106726.27% in 2024, its largest moves.
• Universe Pharmaceuticals' Short term Debt stood at $19723.0 in 2021, then jumped by 17033.62% to $3.4 million in 2022, then soared by 62.24% to $5.5 million in 2023, then soared by 106726.27% to $5.9 billion in 2024, then slumped by 64.02% to $2.1 billion in 2025.
• The last three Short term Debt figures came in at $2.1 billion (Q3 2025), $5.9 billion (Q3 2024), and $5.5 million (Q1 2024), per Business Quant data.